Novel strategies to attenuate the effect of lipopolysaccharide on the immune response

Current Opinion in Infectious Diseases

Volumn 10, Issue 3, 1997, Pages 177-182

  Tanamoto, Ken Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY;

BACTERIAL INFECTION; GRAM NEGATIVE INFECTION; IMMUNE RESPONSE; MEDIATOR; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030996782     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199706000-00004     Document Type: Review

References (66)

1. Ziegler EJ, MCCutchan JA, Fisher CJ Jr, Sprung Cl, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP et al. and the Sepsis Study Group: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991, 324:429-436.
2. Greenman RL, Schein RM, Martin MA, Wenzel RP, Maclntrye NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M- Plouffer J: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991, 266:1097-1102.
3. Pollack M. Koles NL, Preston MJ, Brown BJ, Pier GB: Functional properties of isotype-switched immunoglobulin M (IgM) and IgE monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 1995, 63:4481-4488.
4. Pollack M, Espinoza AM, Guelde G, Koles NL, Wahl LM, Ohl CA: Lipopolysaccharide (LPS)-specific monoclonal antibodies regulate LPS uptake and LPS-induced tumor necrosis factor-α responses by human monocytes. J Infect Dis 1995, 172:794-804.
5. Frasa H, Benaissa-trouw B, Tavares L, Van Kessel K, Poppelier M, Kraaijeveld K, Verhoef J: Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice. Infect Immun 1996, 64:775-781.
6. Emancipator K, Csako G, Elin RJ: In-vivo inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992, 60:596-601.
7. Harris HW, Grunfeld C, Feingold KR, Rapp JH: Human VLDL and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990, 86:696-701.
8. Netea MG, Demacker PNM, Kullberg BJ, Boerman OC, Verschueren I, Stalenhoef AFH, van der Meer JWM: Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest 1996, 97:1366-1372 This paper describes the effect of endogenously elevated LDL on survival and cytokine production after a lethal challenge with either LPS or live Gramnegative bacteria in LDL receptor-deficient mice.
9. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, Cate JW, van Deventer SJH: Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996, 184:1601-1608 This study demonstrated that reconstituted HDL inhibited LPS effects in humans not only by binding and neutralizing LPS but also by reducing CD 14 expression on monocytes.
10. van der Poll T, Braxton CC, Coyle SM, Boermeester MA, Wang JCL, Jansen PM, Montegut WJ, Calvano SE, Hack CE, Lowry SF: Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun 1995, 63:3396-3400.
11. Mey A, Leffler H, Hmama Z. Normier G. Revillard JP: The animal lectin galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. J Immunol 1996, 156: 1572-1577.
12. Ried C, Wahl C, Miethke T, Wellnhofer G, Landgraft C, Schneider-Mergener J, Hoess A: High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. J Biol chem 1996, 271:28120-28127 This study describes the minimal requirements of rLALF for LPS binding and its neutralization, by using synthetic peptides comprising different parts of rLALF.
13. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995, 374:1-5.
14. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M: Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 1996, 271:28375-28381.
15. Elass-Rochard E, Roseanu A, Legrand D, Trif M, Salvon V, Motas C, Montreuil J, Spik G: Lactoferrni-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli O55B5 lipopolysaccharide. Biochem J 1995, 312:839-845.
16. Falla TJ, Karunaratne DN, Hancock REW: Mode of action of the antimicrobial peptide indolicidin. J Biol Chem 1996, 271:19298-19303 This paper describes the mechanism of action of indolicidin and the effect of carboxyl-terminal modification of the peptide by examining its ability to bind and permeabilize Gram-negative bacterial membranes and its effect on polar lipid bilayers.
17. Cai M, Sakamoto A, Ogawa R: Inhibition of nitric oxide formation with L-canavanine. Eur J Pharmacol 1996, 295:215-220.
18. Ruetten H, Southan GJ, Abate A, Thiemermann C: Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1996, 118:261-270.
19. Wu CC, Ruetten H, Thiememann C: Comparison of the effects of aminoguanidine and N'-nitro-L-argnine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur J Pharmacol 1996, 300:99-104.
20. Gardiner SM, Kemp PA, March JE, Benett T: Effects of dexamethasone and SB 209670 on the regional haemodynamic respnoses to lipopolysaccharide in conscious rats. Br J Pharmacol 1996, 118:141-149.
21. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996, 97:713-719.
22. Benigni F, Sacco S, Pennica D, Ghezzi P: Cardiotrophin-1 inhibits tumor necrosis factor production in the heart and serum of lipopolysacharide-treated mice and in vitro in mouse blood cells. Am J Pathol 1996, 149:1847-1850.
23. Zinetti M, Galli G, Demitri MT, Fantuzzi G, Minto M, Ghezzi P, Alzani R, Cozzi E, Fratelli M: Chlorpromazine inhibits tumour necrosis factor synthesis and Cytotoxicity in vitro. Immunology 1995, 86:416-421.
24. De Catro CMMB, Nahori MA, Dumary CH, Vargaftig BB, Bachelet M: Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia. Eur J Pharmacol 1995, 294:669-676.
25. Gonzalez PK, Zhuang J, Doctrow SR, Malfroy B, Benzon PF, Menconi MJ, Fink MP: EUK-8, a syntheitc superoxide dismutase and catalase mimetic, ameliorates acute lung injury in endotoxemic swine. J Pharmacol Exp Ther 1995, 275:798-806.
26. Sewerynek E, Melchiorri D, Reiter RJ, Ortiz GG, Lewinski A: Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 1995, 293:327-334.
27. Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J, Sherry B, Schmidtmayerova H, Calandra T, Zhang X, Bukrinsky M et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med 1996, 183:927-936 This paper reports that tetravalent guanylhydrazone compound effectively suppresses several functional components of the activated macrophage phenotype, including the induction of proinflammatory cytokines, inducible nitric oxide synthase and L-arginine uptake in LPS-stimulated monocyte/macrophages.
28. Chiao H, Foster S, Thomas R, Lipton J, Star RA: α-Melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest 1996, 97:2038-2044 This study examines the effects of α-melanocyte-stimulating hormone on LPS-induced changes in hepatic enzyme release, morphology, cytokines, and chemokines to understand the anti-inflammatory mechanisms of α-melanocyte-stimulating hormone in vivo.
29. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A: Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 1996, 64:825-828.
30. Denlinger LC, Fisette PL, Garis KA, Kwon G, Vazquez-Torres A, Simon AD, Nguyen B, Proctor RA, Bertics PJ, Corbett JA: Regulation of inducible nitric oxide synthase expression by macrophage purinoceptors and calcium. J Biol Chem 1996, 271:337-342.
31. Hasko G, Szabo C, Merkel K, Bencsics A, Zingarelli B, Kvetan V, Vizi ES: Modulation of lipopolysaccharide-induced tumor necrosis factor-α and nitric oxide production by dopamine receptor agonists and antagonists in mice. Immunol Lett 1996, 49:143-147.
32. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M: Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 1996, 314:137-142.
33. de Waal Malefyt R, Abrams J, Bennet B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
34. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995, 155:4909-4916.
35. Marcelletti JF: IL-10 inhibits lipopolysaccharide-induced murine B cell proliferation and cross-linking of surface antigen receptors or ligation of CD40 restores the response. J Immunol 1996, 156:3323-3333.
36. Arai T, Hiromatsu K, Kobayashi N, Takano M, Ishida H, Nimura Y, Yoshikai Y: IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J Immunol 1995, 155:5743-5749.
37. Smith SR, Terminelli C, Denhardt G, Narula S, Thorbecke GJ: Administration of interleukin-10 at the time of priming protects Corynebacterium parvum-primed mice against LPS- and TNF-α-induced lethality. Cell Immunol 1996, 173:207-214.
38. Santucci L, Fiorucci S, Chiorean M, Brunori PM, Matteo FM, Sidoni A, Migliorati G, Morelli A: Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. Gastroenterology 1996, 111:736-744.
39. Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N, Grünig G, Rennick D: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxin shock and the Shwartzman re-action but not endotoxin tolerance. J Clin Invest 1995, 96:2339-2347
40. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330: 662-664.
41. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU: A phase I trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988, 6:1328-1334.
42. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991, 163:83-88.
43. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R et al, and TNF mAb Sepsis Study Group: Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 1995, 273:934-941.
44. Mastroeni P, Skepper JN, Hormaeche CE: Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections. Infect Immun 1995, 63:3674-3682.
45. Suffredini AF, Reda D, Branks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptors on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995, 155:5038-5045.
46. Møller B, Ellermann-Eriksen S, Storgaard M, Obel N, Bendtzen K, Petersen CM: Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. J Intect Dis 1996, 174:557-563.
47. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor : Fc fusion protein. N Engl J Med 1996, 334:1697-1702 Treatments with TNF-receptor : Fc fusion protein not only reduce mortality in patients with septic shock, but even appear to increase mortality at higher doses.
48. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD. Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431
49. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
50. Lee JD, Kato K, Tobias PS, Kirkland TN, Ulevitch RJ: Transfection of CD14 into 70z/3 cells dramatically enhances the sensitivity to complex of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 1992, 175:1697-1705.
51. Weinstein SL, Gold MR, Defranco AL: Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. Proc Natl Acad Sci USA 1991, 88:4148-4152.
52. Vanichkin A, Patya M, Gazit A, Levitzki A, Novogrodsky A: Late administrations of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. J Infect Dis 1996, 173:927-933.
53. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W: Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996, 226:810-818.
54. Ohlsson BG, Englund MCO, Karlsson ALK, Knutsen E, Erixon C, Skribeck H, Liu Y, Bondjers G, Wiklund O: Oxidized low-density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-κB to DNA and the subsequent expression of tumor necrosis factor-α and interleukin-1β in macrophages. J Cln Invest 1996. 98:78-89.
55. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ: Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996, 98:1533-1538 This study demonstrated that the anti-CD14 monoclonal antibody treatment prevented profound hypotension, reduced plasma cytokine levels (TNF, IL-1, IL-6 and IL-8) and inhibited the alteration in lung epithelial permeability in primates challenged with LPS.
56. 2 with concomitant reduction of cytokine production. Infect Immun 1995, 63:4812-4817.
57. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM: Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol 1994, 152:5868-5876.
58. Landmann R, Zimmerli W, Sansano S, Links S, Hahn A, Glauser MP, Calandra T: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995, 171:639-644.
59. Landmann R, Reber AM, Sansano S, Zimmerli W: Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996, 173:661-668.
60. Gupta D, Kirkland TN, Viriyakosol S, Dziarski R: CD14 is a cell-activating receptor for bacterial peptidoglycan. J Biol Chem 1996, 271:23310-23316.
61. Kusunoki T, Hailman E, Juan TSC, Lichenstein HS, Wright SD: Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995, 182:1673-1682.
62. Tanamoto K, Galanos C, Luderitz O, Kusumoto S, Shiba T: Mitogenic activities of synthetic lipid A analogs and suppression of mitogenicity of lipid A. Infect Immun 1984, 44:427-433.
63. Somerville JE, Cassiano L, Bainbridge B, Cunningham MD, Darveau RP: A novel Escherichia coli lipid A mutant that produces an anti-inflammatory lipopolysaccharide. J Clin Invest 1996, 97:359-365.
64. Aida Y, Kusumoto K, Nakalomi K, Takada H, Pabst MJ, Maeda K: An analogue of lipid A and LPS from Rhodobactor sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. J Leukoc Biol 1995, 58:675-682.
65. Sato K, Fujihara M, Takahashi TA, Yoo YC, Hata K, Tono-oka S, Suzuki T, Sekiguchi S, Azuma I: Endotoxin antagonism by a synthetic lipid A analogue, DT-5461, with low endotoxicity in human peripheral blood monocytes. Biochem Biophys Res Commun 1995, 216:367-374.
66. Tanamoto K: Chemically detoxified lipid A precursor derivatives antagonize the TNF-α-inducing action of LPS in both murine macrophages and a human macrophage cell line. J Immunol 1995, 155:5391-5396 This study reported that the biologically active lipid A precursor lost its activity completely by both succinylation and acetylation, and the chemically detoxified derivatives antagonized the LPS action in both murine and human cells.